The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I/II study of TROP2 CAR engineered IL15-transduced cord blood-derived NK cells delivered intraperitoneally for the management of platinum resistant ovarian cancer, mesonephric-like adenocarcinoma, and pancreatic cancer.
 
Anne Knisely
No Relationships to Disclose
 
Hind Rafei
Patents, Royalties, Other Intellectual Property - H.R. and The University of Texas MDACC have an institutional financial conflict of interest with Takeda Pharmaceuticals for the licensing of the technology related to CAR-NK cell research (Inst)
 
Rafet Basar
Research Funding - Takeda (Inst)
Patents, Royalties, Other Intellectual Property - Institutional financial conflict of interest with Takeda Pharmaceutical for the licensing of the technology related to CAR NK cells research.
 
Pinaki Prosad Banerjee
Patents, Royalties, Other Intellectual Property - PPB and The University of Texas MD Anderson Cancer Center (MDACC) have an institutional financial conflict of interest with Takeda Pharmaceutical for the licensing of the technology related to CAR-NK cell research. MD Anderson has implemented an Instituti
 
Zeyad Metwalli
No Relationships to Disclose
 
Kathryn Lito
No Relationships to Disclose
 
Bryan M. Fellman
No Relationships to Disclose
 
Ying Yuan
Consulting or Advisory Role - A2 Biotherapeutics; Abbvie; Amgen; Ascendis Pharma; Bexion; BeyondSpring Pharmaceuticals; Boehringer Ingelheim; Bristol-Myers Squibb/Celgene/Juno; Century Therapeutics; Enliven Therapeutics; GT Medical Technologies; NeoImmuneTech; NGM Biopharmaceuticals; Repare Therapeutics; SERVIER; Starpax Medical; Vertex
 
Robert A. Wolff
Honoraria - Conveners; Emirates Oncology Society
Patents, Royalties, Other Intellectual Property - Royalties from McGraw-Hill: Editor: M.D. Anderson Manual of Medical Oncology, 3rd edition.
 
Maria Pia Morelli
No Relationships to Disclose
 
Larissa Alejandra Meyer
Employment - Gulf Coast Vascular Partners (I)
Stock and Other Ownership Interests - Bristol-Myers Squibb; crispr therapeutics; Denali Therapeutics; InVitae; Johnson & Johnson
Research Funding - AstraZeneca; Merck
Other Relationship - Bristol-Myers Squibb/Medarex
 
Xin Shelley Wang
Patents, Royalties, Other Intellectual Property - Symptom Assessment Systems, LLC
 
Shannon Neville Westin
Consulting or Advisory Role - AstraZeneca; BioAscent; Caris Life Sciences; Clovis Oncology; Curio Science; Eisai; EQRX; Genentech; Gerson Lehrman Group; Gilead Sciences; GlaxoSmithKline; Immunocore; Immunogen; Lilly; Medscape; Merck; Mereo BioPharma; Mersana; Mersana; NGM Biopharmaceuticals; Nuvectis Pharma; Nuvectis Pharma; OncLive; pharma&; Roche; Seagen; Targeted Oncology; Vaniam Group; Verastem; Vincerx Pharma; Zentalis; ZielBio
Research Funding - AstraZeneca (Inst); Avenge Bio (Inst); Bayer (Inst); Bio-Path Holdings, Inc (Inst); Clovis Oncology (Inst); GlaxoSmithKline (Inst); GOG Foundation (Inst); Jazz Pharmaceuticals (Inst); Mereo BioPharma (Inst); Novartis (Inst); Nuvectis Pharma (Inst); Roche/Genentech (Inst); Zentalis (Inst)
 
Funda Meric-Bernstam
Employment - MD Anderson Cancer Center
Honoraria - Dava Oncology
Consulting or Advisory Role - Abbvie; AstraZeneca; Black Diamond Therapeutics; Calibr; Daiichi Sankyo/Astra Zeneca; EcoR1 Capital; Eisai; Exelixis; GT Aperion; Incyte; Infinity Pharmaceuticals; Karyopharm Therapeutics; LegoChem Biosciences; Lengo Therapeutics; Menarini Group; OnCusp Therapeutics; Protai; Seagen; Tallac Therapeutics; Theratechnologies; Zentalis; Zymeworks
Research Funding - Abbvie (Inst); Aileron Therapeutics (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Calithera Biosciences (Inst); Curis (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Debiopharm Group (Inst); eFFECTOR Therapeutics (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Guardant Health (Inst); Jazz Pharmaceuticals (Inst); Klus Pharma (Inst); Novartis (Inst); Pfizer (Inst); PUMA Biotechnology (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - ARTIDIS; Cholangiocarcinoma Foundation; Dava Oncology; ESMO; European Organisation for Research and Treatment of Cancer (EORTC)
 
Elizabeth J. Shpall
Honoraria - Bayer
Consulting or Advisory Role - Adaptimmune; AXIO Research; Celaid Therapeutics; Fibrobiologics; Navan; NY Blood Center
Patents, Royalties, Other Intellectual Property - Affimed Therapeutics; Syena; Takeda
Travel, Accommodations, Expenses - Magenta Therapeutics; Novartis
 
Karen H. Lu
No Relationships to Disclose
 
Katy Rezvani
Consulting or Advisory Role - Avenge Bio; Bayer; Caribou Biosciences; GEMoaB; GlaxoSmithKline; NAVAN Technologies; Virogen
Research Funding - Affimed Therapeutics; Pharmacyclics; Takeda
Patents, Royalties, Other Intellectual Property - License agreement and research agreement with Affimed which creates an institutional conflict of interest under MD Anderson policy.; License agreement and research agreement with Affimed which creates an institutional conflict of interest under MD Anderson policy. (Inst); License agreement and research agreement with Takeda to develop CB-CAR NK cells for the treatment of B-cell malignancies and other cancers, which creates an institutional conflict of interest under MD Anderson policy; License agreement and research agreement with Takeda to develop CB-CAR NK cells for the treatment of B-cell malignancies and other cancers, which creates an institutional conflict of interest under MD Anderson policy (Inst); Patent on generation of BKV CTLs for the treatment of HC or PML; Patent on generation of CAR NK cells
 
Amir A. Jazaeri
Stock and Other Ownership Interests - Avenge Bio; Greenfire Bio
Honoraria - Gerson Lehrman Group; Guidepoint Global
Consulting or Advisory Role - Adicet Bio; Iovance Biotherapeutics; Macrogenics; Theolytics
Research Funding - Aravive (Inst); AstraZeneca (Inst); Avenge Bio (Inst); Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); immatics (Inst); Imunon (Inst); Iovance Biotherapeutics (Inst); Lilly (Inst); Lixte Biotechnology (Inst); Macrogenics (Inst); Merck (Inst); Pfizer (Inst); Xencor (Inst)
Travel, Accommodations, Expenses - Stryker